Erythropoietic protoporphyria

SCENESSE® to be Prescribed in China

Retrieved on: 
Thursday, April 23, 2020
Cities in China, Sub-provincial cities in the People's Republic of China, Food safety in China, National Medical Products Administration, Erythropoietic protoporphyria, Hainan Airlines, Hangzhou, Afamelanotide, Guangzhou

Under an exclusive Collaboration Agreement, CLINUVEL and Winhealth Pharma will distribute SCENESSE and train and accredit local hospitals to provide long-term care to Chinese EPP patients.

Key Points: 
  • Under an exclusive Collaboration Agreement, CLINUVEL and Winhealth Pharma will distribute SCENESSE and train and accredit local hospitals to provide long-term care to Chinese EPP patients.
  • Clinical data generated in the United States and European Union, as well as under the Named Patient Program in China, will be filed to the National Medical Product Administration (NMPA) to obtain full registration of SCENESSE.
  • EPP is a severe rare disorder in China representing an unmet medical need, Winhealths Chair and CEO, Mr Jack Wang said.
  • Headquartered in Hong Kong, China, WINHEALTH has operation centres and offices in Hangzhou, Shanghai, Beijing, Guangzhou, Hainan, Tokyo and Munich.

Innovative drug launched for rare, isolating, “light intolerance” disorder

Retrieved on: 
Thursday, April 16, 2020
Life sciences, Articles, Sun tanning, Ultraviolet radiation, Electromagnetic radiation, Electromagnetic spectrum, Ultraviolet, Specialty drugs in the United States, Photoprotection, Food and Drug Administration, Erythropoietic protoporphyria

Just one in 140,000 Americans is thought to live with EPP, an inherited disorder which causes debilitating invisible reactions whenever patients expose themselves to visible light, particularly sunlight.

Key Points: 
  • Just one in 140,000 Americans is thought to live with EPP, an inherited disorder which causes debilitating invisible reactions whenever patients expose themselves to visible light, particularly sunlight.
  • The innovation SCENESSE was approved by the US Food and Drug Administration (FDA) in October as the worlds first systemic photoprotective drug, a hormone protecting patients against any light source and ultraviolet (UV) radiation.
  • More than 30 US insurers nationwide have introduced coverage of SCENESSE through Prior Authorization, acceptance as a specialty drug, or inclusion in their formulary.
  • These patients have lived, lifelong, as social recluses, filled with anxiety towards any light sources.

Global Expanded Polypropylene (EPP) Foam Market (2019 to 2025) - Players Profiled Include JSP, Kaneka & Hanwha Chemical Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 26, 2020
Automotive Manufacturing, Other Manufacturing, Manufacturing, Organic polymers, Organic compounds, Commodity chemicals, Packaging materials, Thermoplastics, Goods economics), Dielectrics, Plastics, Polypropylene, Erythropoietic protoporphyria, Polystyrene

The EPP foam market is projected to grow from USD 1,253 Million in 2019 to USD 1,619 Million by 2024, at a CAGR of 5.3% between 2019 and 2024.

Key Points: 
  • The EPP foam market is projected to grow from USD 1,253 Million in 2019 to USD 1,619 Million by 2024, at a CAGR of 5.3% between 2019 and 2024.
  • Recyclable & reusable properties, optimum performance, and low weight of EPP foam are driving the market.
  • Automotive is estimated to have the largest share of the overall EPP foam market during the forecast period.
  • It is projected to offer significant opportunities for vehicle manufacturers, and in turn, EPP foam manufacturers in the next five years.

Expanded Polypropylene (EPP) Foam Market Worth $1,619 Million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, March 16, 2020
Foams, Colloids, Matter, Physical sciences, Chemistry, Epp, Erythropoietic protoporphyria, Plastics

High-density EPP foams possess high compressive strength and energy absorption characteristics compared to low-density EPP foams.

Key Points: 
  • High-density EPP foams possess high compressive strength and energy absorption characteristics compared to low-density EPP foams.
  • The APAC EPP foam market is segmented into China, Japan, India, South Korea, and the Rest of APAC.
  • The EPP foam market in APAC is projected to witness the highest CAGR in the next five years.
  • The growth can be attributed to Recyclable & reusable properties, optimum performance, and low weight of EPP foam.

Expanded Polypropylene (EPP) Foam Market Worth $1,619 Million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, March 16, 2020
Foams, Colloids, Matter, Physical sciences, Chemistry, Epp, Erythropoietic protoporphyria, Plastics

High-density EPP foams possess high compressive strength and energy absorption characteristics compared to low-density EPP foams.

Key Points: 
  • High-density EPP foams possess high compressive strength and energy absorption characteristics compared to low-density EPP foams.
  • The APAC EPP foam market is segmented into China, Japan, India, South Korea, and the Rest of APAC.
  • The EPP foam market in APAC is projected to witness the highest CAGR in the next five years.
  • The growth can be attributed to Recyclable & reusable properties, optimum performance, and low weight of EPP foam.

Erythropoietic Protoporphyria - Pipeline Insight, 2020

Retrieved on: 
Monday, February 24, 2020
Medicine, Branches of biology, Organ systems, Porphyrias, RTT, Erythropoietic protoporphyria, Erythropoietin

DUBLIN, Feb. 24, 2020 /PRNewswire/ -- The "Erythropoietic Protoporphyria - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 24, 2020 /PRNewswire/ -- The "Erythropoietic Protoporphyria - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Erythropoietic Protoporphyria pipeline landscape is provided, which includes the disease overview and Erythropoietic Protoporphyria treatment guidelines.
  • The assessment part of the report embraces in-depth Erythropoietic Protoporphyria commercial assessment and clinical assessment of the Erythropoietic Protoporphyria pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Erythropoietic Protoporphyria emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Erythropoietic Protoporphyria?

FDA Approves SCENESSE® For Genetic Disorder

Retrieved on: 
Wednesday, October 9, 2019
Health, Articles, Pharmaceutical industry, Drug discovery, Rare diseases, Food and Drug Administration, United States Public Health Service, Clinical trial, European Medicines Agency, Phototoxicity, Erythropoietic protoporphyria, Afamelanotide

MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute intolerance to light.

Key Points: 
  • MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute intolerance to light.
  • In 2014, SCENESSE was approved by the European Medicines Agency for EPP.
  • SCENESSE (afamelanotide16mg) is approved in the European Union as an orphan medicinal product for the prevention of phototoxicity in adult patients with EPP.
  • Phase III clinical trials of SCENESSE have been published in the New England Journal of Medicine, see:
    Langendonk et al (2015).

FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder

Retrieved on: 
Tuesday, October 8, 2019
Branches of biology, Organ systems, Porphyrias, Hair color, Skin pigmentation, Rare diseases, RTT, Erythropoietic protoporphyria, Ferrochelatase, Melanocortin 1 receptor, Heme, Afamelanotide

"For patients who are suffering from erythropoietic protoporphyria, a rare disorder, exposure to light may be extremely painful.

Key Points: 
  • "For patients who are suffering from erythropoietic protoporphyria, a rare disorder, exposure to light may be extremely painful.
  • Erythropoietic protoporphyria is a rare disorder caused by mutations leading to impaired activity of ferrochelatase, an enzyme involved in heme production.
  • Light reaching the skin can react with PPIX causing intense skin pain and skin changes, such as redness and thickening.
  • Scenesse (afamelanotide), a melanocortin-1 receptor (MC1-R) agonist, increases the production of eumelanin in the skin independent of exposure to sunlight or artificial light sources.

High Performance Polymers: Meet the Quadrant Experts at OTC 2018 in Houston, TX

Retrieved on: 
Monday, April 23, 2018
Islamic astronomy, Islamic technology, Quadrant, Surveying, Erythropoietic protoporphyria, Epp, Equipment, Technology, Science and technology

The seals have 15+ years proven performance, reducing tolerance or maintaining original tolerance over their lifetime, providing improved compressor efficiency.

Key Points: 
  • The seals have 15+ years proven performance, reducing tolerance or maintaining original tolerance over their lifetime, providing improved compressor efficiency.
  • Quadrant materials comply with many common industry specifications, including NORSOK, ISO, ACME, API, and NACE, delivering reliability, safety, and efficiency.
  • Visit Quadrant EPP at the 2018 Offshore Technology Conference (booth #161) at NRG Park in Houston, Texas from April 30th May 3rd, 2018.
  • Learn more about Quadrant EPP at http://www.quadrantplastics.com or connect with Quadrant EPP on Facebook , YouTube , and Twitter ("quadrantepp").